US Food and Drug Administration approval of Incyte Corporation and Syndax Pharmaceuticals, Inc.’s Niktimvo (axatilimab-csfr) in chronic graft-versus-host disease (GVHD) sets the stage for competition with Sanofi’s Rezurock (belumosudil). It also rockets Syndax into the commercial stage as a company, with approval expected for revumenib in acute leukemia drug early in the fourth quarter, and it gives Incyte another product in the chronic GVHD space beyond its JAK inhibitor Jakafi (ruxolitinib), which will lose market exclusivity in four years.
The two companies announced the FDA approval of Niktimvo for chronic GVHD in patients who have had two prior lines...
